Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.73 |
| ▸ | CA1 | P00915 | 2/20 | 0.73 |
| ▸ | CA2 | P00918 | 2/20 | 0.73 |
| ▸ | CA4 | P22748 | 2/20 | 0.73 |
| ▸ | CA6 | P23280 | 2/20 | 0.73 |
| ▸ | CA7 | P43166 | 2/20 | 0.73 |
| ▸ | CA9 | Q16790 | 2/20 | 0.73 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.73 |
| ▸ | TPMT | P51580 | 1/20 | 0.73 |
| ▸ | TSHR | P16473 | 4/20 | 0.63 |
| ▸ | TTR | P02766 | 2/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3924278 | 0.93 | CA12 (0.73) | CA12CA1CA2CA4CA6 | |
| SCHEMBL3545163 | 0.91 | KMT2A (0.58) | CA12CA1CA2CA4CA6 | |
| SCHEMBL1554712 | 0.88 | CA12 (0.71) | CA12CA1CA2CA4CA6 | |
| SCHEMBL5466423 | 0.86 | ALDH1A1 (0.56) | CA12CA1CA2CA4CA6 | |
| Veratric Acid SCHEMBL29386353 | 0.85 | CA12 (1.00) | CA12CA1CA2CA4CA6 | |
| Veratric Acid SCHEMBL976032 | 0.85 | CA12 (1.00) | CA12CA1CA2CA4CA6 | |
| Veratric Acid SCHEMBL114848 | 0.85 | CA12 (1.00) | CA12CA1CA2CA4CA6 | |
| SCHEMBL25139437 | 0.85 | HIF1A (0.53) | CA12CA1CA2CA4CA6 | |
| SCHEMBL24812339 | 0.85 | MAPK1 (0.62) | CA12CA1CA2CA4CA6 | |
| SCHEMBL6568018 | 0.85 | MAPT (0.66) | CA12CA1CA2CA4CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12053459-B2 | CDK2 inhibitors and methods of using the same | CEDILLA THERAPEUTICS, INC. (MA) | 2024-08-06 | — | — | US | disclosed |
| EP-4358954-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | Cedilla Therapeutics, Inc. (US) | 2024-05-01 | — | — | EP | disclosed |
| CN-117561058-A | CDK2 inhibitors and methods of use thereof | 塞迪拉治疗股份有限公司 | 2024-02-13 | — | — | CN | disclosed |
| US-20230159504-A1 | 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-25 | — | — | US | disclosed |
| US-20230121337-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. | 2023-04-20 | — | — | US | disclosed |
| US-20230121337-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. | 2023-04-20 | — | — | US | disclosed |
| WO-2022272106-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| WO-2022272106-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| US-20220402908-A1 | CXCR6 INHIBITORS AND METHODS OF USE | Sanford Burnham Prebys Medical Discovery Institute | 2022-12-22 | — | — | US | disclosed |
| US-20220396581-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS | Janssen Biopharma, Inc. (US) | 2022-12-15 | — | — | US | disclosed |
| EP-2271643-B1 | OXADIAZOLES AS S1P1 RECEPTOR AGONISTS | GLAXO GROUP LTD (GB) | 2012-08-15 | — | — | EP | disclosed |
| WO-2012106499-A1 | PYRROLOPYRAZINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-09 | — | — | WO | disclosed |
| US-20120196869-A1 | PYRROLOPYRAZINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2012-08-02 | — | — | US | disclosed |
| US-20120196869-A1 | PYRROLOPYRAZINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2012-08-02 | — | — | US | disclosed |
| US-20120196869-A1 | PYRROLOPYRAZINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2012-08-02 | — | — | US | disclosed |
| US-20110039889-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2011-02-17 | — | — | US | disclosed |
| EP-2271643-A1 | COMPOUNDS | Glaxo Group Limited (GB) | 2011-01-12 | — | — | EP | disclosed |
| US-7781373-B2 | Stabilized dyes for thermal dye transfer materials | EASTMAN KODAK COMPANY (US) | 2010-08-24 | — | — | US | disclosed |
| WO-2009133136-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-11-05 | — | — | WO | disclosed |
| US-20080182212-A1 | STABILIZED DYES FOR THERMAL DYE TRANSFER MATERIALS | ENCINA PRIVATE CREDIT SPV 2, LLC, AS COLLATERAL AGENT | 2008-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039889-A1 | COMPOUNDS | CYP11B2, CYP11B1, GLS2 | CA12 3483/4885CA1 3853/4885CA2 1833/4885 |
| US-20220396581-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS | MAVS, SARS1, ZC3HAV1 | CA12 3612/4885CA1 4798/4885CA2 3446/4885 |
| US-20230121337-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CDK2, CDK20, CDK2AP2 | CA12 3738/4885CA1 3559/4885CA2 2753/4885 |
| US-20220402908-A1 | CXCR6 INHIBITORS AND METHODS OF USE | CXCR6, CXCR1, CXCR5 | CA12 1476/4885CA1 2119/4885CA2 2409/4885 |
| US-12053459-B2 | CDK2 inhibitors and methods of using the same | CDK2, CDK20, CDK2AP2 | CA12 3738/4885CA1 3559/4885CA2 2753/4885 |
| US-20120196869-A1 | PYRROLOPYRAZINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | KCNJ2, KCNJ5, KCNJ1 | CA12 4097/4885CA1 1844/4885CA2 239/4885 |
| US-20230159504-A1 | 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | SERPINA2, SERPINB1, SERPINE1 | CA12 4854/4885CA1 4779/4885CA2 4793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.